A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified February 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Aranesp | Cardiology | Cardiovascular | Dialysis | Epogen | Heart | Mircera | Polyethylene Glycol | Procrit | Research | Study